A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
A Multicenter, Comparative, Randomized, Double-Blind, Placebo Controlled Study on the Effect on Weight of Adjunctive Treatment With Aripiprazole in Patients With Schizophrenia.
Sponsor: Otsuka America Pharmaceutical
This PHASE4 trial investigates Schizophrenia and is currently completed. Otsuka America Pharmaceutical leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka America Pharmaceutical
- Otsuka Pharmaceutical Development & Commercialization, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antalya, Turkey (Türkiye) , Augsburg, Germany , Bellville, South Africa , Berlin, Germany , Bern, Switzerland , Brno-Bohunice, Czechia , Bromma, Sweden , Brumath, France , Budapest, Hungary , Bully-les-Mines, France and 47 more locations